olaparib,abiraterone
astrazeneca,merck,janssen
['propel', 'brca', 'crpc']
 propel ph3 study show clearly benefit of abi + olap. mainly for brcam + pts (85/796 pts ~10%) pend. os data!! #esmo2022 please testing all mcrpc pts 
Medical Oncologist. Involved in GU tumors oncology. Adjunct Assoc. Professor UCM. Executive member SOGUG Foundation. Hospital Univ. 12 de Octubre. Madrid.